Biomea Fusion, Inc. Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax
Biomea Fusion, Inc. (BMEA) had Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax of $0 as of 2023-09-30, per its 10-Q filed 2023-10-30.
Discontinued › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss
us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax · last filed 2024-03-28
- 2023-09-30: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax $0.00.
- 2023-06-30: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax $0.00.
- 2023-03-31: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax $0.00.
- 2022-12-31: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax $1.00K.
| Period end | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax |
|---|---|
| 2023-09-30 | $0.00 10-Q · filed 2023-10-30 |
| 2023-06-30 | $0.00 10-Q · filed 2023-07-31 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-02 |
| 2022-12-31 | $1.00K 10-K · filed 2024-03-28 |
| 2022-09-30 | $13.00K 10-Q · filed 2022-11-07 |
| 2022-06-30 | $17.00K 10-Q · filed 2022-08-01 |
| 2022-03-31 | $23.00K 10-Q · filed 2022-05-16 |
| 2021-12-31 | $11.00K 10-K · filed 2023-03-28 |
| 2021-09-30 | $4.00K 10-Q · filed 2021-11-03 |
| 2021-06-30 | $2.00K 10-Q · filed 2021-08-11 |
| 2021-03-31 | $15.00K 10-Q · filed 2021-05-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |